Machine Learning Tool Predicts a Child’s Cisplatin-Induced Hearing Loss Risk
This tool allows doctors to tailor interventions like hearing monitoring or STS use based on each child’s specific risk of cisplatin-induced hearing loss.
Read More
Search Results for: cisplatin
Oncologist Researching Cisplatin Alternative for Cancer Patients
An oncologist is seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin.
Read More
Sensorion Enrolls Last Patient in Clinical Trial of Drug to Prevent Cisplatin-Induced Ototoxicity
Sensorion has completed patient enrollment for its Phase 2a NOTOXIS trial, evaluating SENS-401’s potential to prevent Cisplatin-induced ototoxicity.
Read More
Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity
Sensorion was recommended to continue the study of a drug candidate for the prevention of Cisplatin-Induced Ototoxicity (CIO).
Read More
Acousia Therapeutics’ Clinical Trial to Address Hearing Loss from Cisplatin
Acousia Therapeutics received approval for its Phase 2 clinical trial of the otoprotectant ACOU085 for cisplatin-induced hearing loss.
Read More
Cisplatin Dosing, Delivery May Affect Hearing Loss
The study establishes “the first benchmarks for the prevalence of hearing loss,” and reveals that the risk of hearing loss is affected not only by how much drug is given, but by how that drug is delivered—dosing schedules, complementary treatments, and more.
Read More
Sodium Thiosulfate May Help Reduce Cisplatin-Related Hearing Loss, New Study Says
The study showed that STS administered six hours after Cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Read More
Fennec Pharmaceuticals’ Cisplatin-Ototoxicity Treatment Given Breakthrough Therapy Designation
According to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.
Read More
NIH Researchers Find Link Between Cisplatin Build-up and Hearing Loss
Using a highly sensitive technique to measure and map cisplatin in mouse and human inner ear tissues, researchers found that forms of cisplatin build up in the inner ear.
Read More
Otomagnetics Reduces Cisplatin-Related Hearing Loss in Mice, New Study Shows
Using a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%.
Read More
Hearing Loss Can Result from Cisplatin Therapy for Cancer
Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University, who found that increased doses of cisplatin were associated with increased hearing loss.
Read MoreChemotherapy Drugs And Hearing Problems: Pharmacokinetics May Explain Differences In Cisplatin And Oxaliplatin Ototoxicity
More cisplatin enters the inner ear in an animal model than oxaliplatin. The difference may explain why cisplatin treatment in humans can lead to hearing problems while oxaliplatin rarely does.
Read MoreAmifostine lowers risk of cisplatin-related hearing loss in children
A cytoprotective adjuvant used in cancer chemotherapy, amifostine, reduces the likelihood of ototoxicity in children undergoing cisplatin therapy for medulloblastoma, according to a study reported in a recent issue of the Journal of Clinical Oncology.
Read More
Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics’ ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Read More
ASPO Session to Cover Sensorion Audiogene Trial of Pediatric Therapy for Hearing Loss
Sensorion will present early clinical trial results of its gene therapy SENS-501 for treating severe pediatric hearing loss at the 2025 ASPO meeting.
Read More